What is the clinical treatment effect of Erlotinib/Tarceva?

As one of the most widely used targeted drugs in the world, Erlotinib has long occupied an important position in the treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer. As a representative drug of EGFR-TKI, it helps some patients delay disease progression by precisely inhibiting the abnormal signaling pathway of epidermal growth factor receptor. Due to its stable oral administration method, mature application experience and significant benefits for specific genetic groups, erlotinib's clinical status remains stable.

In non-small cell lung cancer, especially in patients with EGFR-sensitive mutations Erlotinib is regarded as one of the standard treatments in overseas guidelines. By blocking EGFR autophosphorylation, the drug reduces the division and invasion of tumor cells and helps improve lesion control. Many overseas professional websites have mentioned that erlotinib can exert stable effects in both initial treatment and post-treatment scenarios, and has predictable long-term management value. Especially among patients who are not suitable for chemotherapy and whose physical status is weak, the convenience of oral targeted drugs has improved treatment adherence.

In patients with locally advanced or metastatic pancreatic cancer, erlotinib is more commonly used as part of combination therapy. Its value lies in reducing the resistance of tumor cells to chemotherapy by inhibiting EGFR signaling, allowing some patients to maintain more stable disease control. Although the overall treatment of pancreatic cancer is difficult, overseas data generally believe that the erlotinib combination regimen has certain significance in specific groups, deepening the exploration of multi-mechanism combination strategies in pancreatic cancer.

In general, the therapeutic effect of erlotinib has three significant characteristics: first, the treatment logic is clear, and the anti-tumor goal is achieved through precise inhibition of the EGFR pathway; second, the beneficiary group is clear, especially in lung cancer with EGFR-sensitive mutations; third, oral administration brings higher compliance, making long-term management more feasible.

Reference materials:https://en.wikipedia.org/wiki/Erlotinib